We have observed
1 EP application
Thomas Claude Philippe Chantereau
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 25, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
USE OF ANTI-MUC1 MAYTANSINOID IMMUNOCONJUGATE ANTIBODY FOR THE TREATMENT OF SOLID TUMORS